Home » FDA Requires Long-Track Approval for Collplant’s Wound Dressing
FDA Requires Long-Track Approval for Collplant’s Wound Dressing
CollPlant Holdings announced that the FDA is requiring the long-track premarket approval, rather than the fast-track 510(k) approval process for the company’s Vergenex wound dressing matrix for chronic wounds.
Globes
Globes
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May